Insider Buying: Mobia Medical (NASDAQ:MOBI) Director Acquires $184,472.86 in Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 15,821 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $11.66 per share, with a total value of $184,472.86. Following the transaction, the director owned 284,725 shares in the company, valued at $3,319,893.50. This represents a 5.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mobia Medical Stock Performance

MOBI stock traded down $0.02 during midday trading on Monday, hitting $11.74. 98,126 shares of the company’s stock were exchanged, compared to its average volume of 92,796. The stock’s fifty day moving average is $12.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The company has a market cap of $390.82 million and a P/E ratio of -0.61. Mobia Medical, Inc. has a one year low of $10.19 and a one year high of $15.29.

Mobia Medical (NASDAQ:MOBI) last posted its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. The firm’s revenue for the quarter was up 102.4% compared to the same quarter last year. On average, analysts expect that Mobia Medical, Inc. will post -2.76 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MOBI. BTIG Research reaffirmed a “buy” rating and set a $19.00 price target on shares of Mobia Medical in a research report on Wednesday, August 12th. Weiss Ratings initiated coverage on shares of Mobia Medical in a research report on Wednesday, August 12th. They issued a “sell (e-)” rating for the company. Bank of America assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set a “buy” rating and a $16.00 price objective on the stock. Wall Street Zen upgraded shares of Mobia Medical from a “sell” rating to a “hold” rating in a research note on Sunday, June 14th. Finally, Zacks Research upgraded Mobia Medical to a “hold” rating in a report on Wednesday, June 3rd. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Mobia Medical presently has an average rating of “Moderate Buy” and a consensus price target of $20.75.

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.